Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Extended Experience with a Very Low Dose, Metronomic, Subcutaneous Decitabine Regimen Intended to Deplete DNMT1 without Cytotoxicity

Ashwin Kishtagari, MBBS, Hassan Awada, Reda Z. Mahfouz, MD PhD, Teodora Kuzmanovic, Jibran Durrani, Cassandra M Kerr, MS, Bhumika J. Patel, MD, Valeria Visconte, PhD, Tomas Radivoyevitch, PhD, Alan Lichtin, MD, Hetty E. Carraway, MD MBA, Jaroslaw P. Maciejewski, MD PhD, Yogenthiran Saunthararajah, MD

Blood (2019) 134 (Supplement_1): 1279.

https://doi.org/10.1182/blood-2019-130579

Published: 2019

Journal Articles

Coexistence of B-Cell Dyscrasia with Large Granular Lymphocytic Leukemia

Hassan Awada, Jibran Durrani, Ashwin Kishtagari, MBBS, Valeria Visconte, PhD, Reda Z. Mahfouz, MD PhD

Blood (2019) 134 (Supplement_1): 3750.

https://doi.org/10.1182/blood-2019-132220

Published: 2019

Journal Articles

Long-Term Experience with Large Granular Lymphocytic Leukemia Evolving after Solid Organ and Hematopoietic Stem Cell Transplantation

Hassan Awada, Reda Z. Mahfouz, MD PhD, Jibran Durrani, Ashwin Kishtagari, MBBS, Deepa Jagadeesh, MDMPH, Alan Lichtin, MD, Brian T. Hill, MD, Betty K. Hamilton, MD, Hetty E. Carraway, MD MBA, Navneet S. Majhail, MD MS, Ronald Sobecks, MD, Valeria Visconte, PhD, Matt Kalaycio, MD, Mikkael A. Sekeres, MD MS, Jaroslaw P. Maciejewski, MD PhD

Blood (2019) 134 (Supplement_1): 1226.

https://doi.org/10.1182/blood-2019-130167

Published: 2019

Journal Articles

Predicting the Outcome in Egyptian Patients with Severe Aplastic Anemia Following Allogeneic Hematopoietic Stem Cell Transplantation Using Matched Sibling Donors

Mai Aly, MD BSc, MS, Hassan Awada, MD, Douaa Sayed, MD, Esam ElBeih, MD, Raafat Abdel El Fattah, MD, Refat Fathy Abdel-Aal Naseer, MD, Reem Alagooz, MD, Rania Hafez, MD, Almetwaly M. Sultan, MD, Nahla El-Sharkawy, MD, Valeria Visconte, PhD, Reda Z. Mahfouz, MD PhD

Blood (2019) 134 (Supplement_1): 5652.

https://doi.org/10.1182/blood-2019-132183

Published: 2019

Journal Articles

Comprehensive Characterization of Cytogenetic and Mutational Analysis of Acute Promyelocytic Leukemia: Is PML-Rara Everything?

Hassan Awada, MD, Jibran Durrani, Tariq Zuheir Kewan, MD, Ashwin Kishtagari, MBBS, Valeria Visconte, PhD, Reda Z. Mahfouz, MD PhD

Blood (2019) 134 (Supplement_1): 1404.

https://doi.org/10.1182/blood-2019-131724

Published: 2019

Journal Articles

Heterozygous CTC1 Variants in Acquired Bone Marrow Failure

Wenyi Shen, MD, Cassandra M. Hirsch, Bartlomiej P. Przychodzen, Reda Z. Mahfouz, MD PhD, Tomas Radivoyevitch, Louis Williams, MD MBA, Mohammad Fahad B. Asad, Jaroslaw P. Maciejewski

Blood (2018) 132 (Supplement 1): 3866.

https://doi.org/10.1182/blood-2018-99-115193

Published: 2018

Journal Articles

The Mechanisms By Which Mutant-NPM1 Uncouples Differentiation from Proliferation Are Reversed By Several Drugs, Enabling Rational Multi-Component Non-Cytotoxic Differentiation Therapy

Xiaorong Gu, PhD, Quteba Ebrahem, MD, Reda Z. Mahfouz, MD PhD, Metis Hasipek, PhD, Francis Enane, PhD, Tomas Radivoyevitch, Nicolas Rapin, PhDMSc, Bartlomiej P. Przychodzen, MSc, Ramesh Balusu, PhD, Claudiu V Cotta, David Wald, MD PhD, Zhenbo Hu, MD PhD, Yosef Landesman, PhD, Maria Paola Martelli, MD PhD, Brunangelo Falini, MD, Hetty E. Carraway, MD MBA, Jaroslaw P. Maciejewski, PhD MD FACP, Babal K Jha, PhD, Yogenthiran Saunthararajah, MD

Blood (2017) 130 (Supplement 1): 878.

https://doi.org/10.1182/blood.V130.Suppl_1.878.878

Published: 2017

Journal Articles

Origins of myelodysplastic syndromes after aplastic anemia

Eiju Negoro, Yasunobu Nagata, Michael J. Clemente, Naoko Hosono, Wenyi Shen, Aziz Nazha, Tetsuichi Yoshizato, Cassandra Hirsch, Bartlomiej Przychodzen, Reda Z. Mahfouz, Teodora Kuzmanovic, Mikkael A. Sekeres, Hideki Makishima, Seishi Ogawa, Jaroslaw P. Maciejewski

Blood (2017) 130 (17): 1953–1957.

https://doi.org/10.1182/blood-2017-02-767731

Published: 2017

Includes: Supplemental data

Journal Articles

Clonal Events of Aplastic Anemia Related to the Evolution to Myelodysplastic Syndrome

Eiju Negoro, MD, PhD, Michael Clemente, M.S., Naoko Hosono, MD,PhD, Aziz Nazha, MD, Wenyi Shen, MD, Yasunobu Nagata, MD, PhD, Cassandra M. Hirsch, BSc, Bartlomiej P Przychodzen, MSc, Reda Z. Mahfouz, MD, PhD, Teodora Kuzmanovic, BSc, Hideki Makishima, MD PhD FACP., Mikkael A. Sekeres, MD MS, Jaroslaw P. Maciejewski, MD, PhD, FACP

Blood (2016) 128 (22): 4290.

https://doi.org/10.1182/blood.V128.22.4290.4290

Published: 2016

Journal Articles

The Mechanism By Which Mutant Nucleophosmin (NPM1) Creates Leukemic Self-Renewal Is Readily Reversed

Xiaorong Gu, PhD, Reda Z. Mahfouz, MD, PhD, Quteba Ebrahem, Francis Enane, Tomas Radivoyevitch, PhD, Michael J. Clemente, M.S., Bartlomiej P Przychodzen, MSc, Zhenbo Hu, MD PhD, Ramesh Balusu, PhD, Claudiu V. Cotta, MD, David N. Wald, MDPhD, Yosef Landesman, PhD, Maria Paola Martelli, MD PhD, Brunangelo Falini, Jaroslaw P Maciejewski, MD PhD FACP, Yogenthiran Saunthararajah, MD

Blood (2016) 128 (22): 444.

https://doi.org/10.1182/blood.V128.22.444.444

Published: 2016

Journal Articles

Myelodysplastic Syndrome (MDS)-Determining Clonal Events at Presentation of Aplastic Anemia (AA)

Eiju Negoro, MD PhD, Naoko Hosono, MDPhD, Wenyi Shen, MD, Tetsuichi Yoshizato, MD, Bhumika J. Patel, Cassandra Hirsh, BSc, Bartlomiej Przychodzen, MSc, Michael J. Clemente, Reda Z. Mahfouz, MDPhD, Aleksandra Wodnar-Filipowicz, PhD, Hideki Makishima, MD PhD, Seishi Ogawa, MD PhD, Mikkael A. Sekeres, MD MS, Jaroslaw P. Maciejewski, MD PhD

Blood (2015) 126 (23): 1652.

https://doi.org/10.1182/blood.V126.23.1652.1652

Published: 2015

Journal Articles

Mechanisms of Resistance to 5-Azacytidine/Decitabine in MDS-AML and Pre-Clinical In Vivo Proof of Principle of Rational Solutions to Extend Response

Quteba Ebrahem, Reda Z. Mahfouz, MDPhD, Lisa Durkin, Mikkael A. Sekeres, MD MS, Anjali S. Advani, MD, Hetty E. Carraway, MD MBA, Sudipto Mukherjee, MD PhD, Betty K. Hamilton, MD, Aaron T. Gerds, MD MS, Ronald Sobecks, MD, Frederic J. Reu, MD, Eric D. Hsi, MD, Jaroslaw P. Maciejewski, MD PhD, Yogenthiran Saunthararajah, MD

Blood (2015) 126 (23): 678.

https://doi.org/10.1182/blood.V126.23.678.678

Published: 2015

Journal Articles

Combination with Thu to Address Pharmacologic Limitations of Decitabine, Interim PK/PD from a Phase 1/2 Clinical Trial of Oral Thu-Decitabine in Sickle Cell Disease

Donald Lavelle, PhD, Michel Gowhari, DO, Michael Pacini, PharmD, Lani Krauz, RN, Johara Hassan, MD, Vinzon Ibanez, Maria A. Ruiz, MSc, Daisy Pacelli, BSc, Chaher Alhandalous, MD, Mitch A. Phelps, PhD, Kathleen Fenner, BS,MS, Reda Z. Mahfouz, MDPhD, John Barnard, Lewis L. Hsu, MD PhD, Victor R. Gordeuk, MD, Joseph DeSimone, PhD, Yogen Saunthararajah, MD, Robert E. Molokie, MD

Blood (2014) 124 (21): 90.

https://doi.org/10.1182/blood.V124.21.90.90

Published: 2014

Journal Articles

A Specific Mechanism By Which NPM1 mutations Impede Myeloid Differentiation Also Explains The Link With DNMT3A Mutation

Xiaorong Gu, PhD, Reda Z Mahfouz, MD/PhD, Francis Enane, MS, Zhenbo Hu, MD, PhD, Michael J. Clemente, Bartlomiej P Przychodzen, PhD, Mikkael A. Sekeres, MD, MS, Anjali S. Advani, MD, Matt Kalaycio, MD, Jaroslaw P. Maciejewski, MD, PhD, Yogen Saunthararajah, M.D.

Blood (2013) 122 (21): 1254.

https://doi.org/10.1182/blood.V122.21.1254.1254

Published: 2013

Journal Articles

Splicing Factor 3b Subunit 1 ( SF3B1) mediates Mitochondrial Iron Overload In Myelodysplastic Syndromes With Ring Sideroblasts By Alternative Splicing Of Mitoferrin-1 ( SLC25A37 )

Blood (2013) 122 (21): 1555.

https://doi.org/10.1182/blood.V122.21.1555.1555

Published: 2013

Journal Articles

BCL -2 Family Of Genes Is a Key Regulator In The Pathogenesis Of SF3B1 Mutant and Wild Type MDS With Ring Sideroblasts and Represents a Novel Drug Target In This Disease

Valeria Visconte, PhD, Reda Z Mahfouz, MD/PhD, Ali Tabarroki, MD, Edy Hasrouni, Heesun J. Rogers, MD, PhD, Yogen Saunthararajah, MD, Brian T. Hill, MD, PhD, Matt Kalaycio, MD, Mikkael A. Sekeres, MD, MS, John Barnard, Ramon V. Tiu, MD

Blood (2013) 122 (21): 263.

https://doi.org/10.1182/blood.V122.21.263.263

Published: 2013

Journal Articles

Splicing Factor 3b Subunit 1 (SF3B1) Heterozygous Mice Manifest a Hematologic Phenotype Similar To Low Risk Myelodysplastic Syndromes With Ring Sideroblasts

Valeria Visconte, PhD, Heesun J. Rogers, MD, PhD, Ali Tabarroki, MD, Li Zhang, Yvonne Parker, Edy Hasrouni, Reda Z Mahfouz, MD/PhD, Quteba Ebrahem, MD, Kyoichi Isono, Haruhiko Koseki, Anjali S. Advani, MD, Yogen Saunthararajah, M.D., Mikkael A. Sekeres, MD, MS, Daniel Lindner, John Barnard, Ramon V. Tiu, MD

Blood (2013) 122 (21): 259.

https://doi.org/10.1182/blood.V122.21.259.259

Published: 2013

Journal Articles

Extra-Nuclear Dislocation of PU.1 but Not CEBPA by Mutated NPM1 in AML Explains Lineage-Associations, ATRA Therapeutic Potential and DNMT3A Secondary Mutation.

Xiaorong Gu, PhD, Reda Z Mahfouz, MD/PhD, Zhenbo Hu, MD, PhD, Yogenthiran Saunthararajah, MD

Blood (2012) 120 (21): 2427.

https://doi.org/10.1182/blood.V120.21.2427.2427

Published: 2012

Journal Articles

Non-Cytotoxic Differentiation Therapy Based On Mechanism of Disease Produces Complete Remission in Myelodysplastic Syndromes (MDS) with High Risk Cytogenetics

Reda Z Mahfouz, MD/PhD, Englehaupt Rickki, Joyce A Juersivich, Kathleen Cooper, RN, MSc, Lisa Durkin, Tomas Radivoyevitch, PhD, Ramon V. Tiu, MD, BS, Frederic J. Reu, MD, Robert M Dean, MD, Ronald Sobecks, MD, Matt Kalaycio, MD, Edward A. Copelan, MD, Anjali Advani, MD, Eric D. Hsi, MD, Mikkael A Sekeres, MD, MS, Jaroslaw P. Maciejewski, MD, PhD, Yogenthiran Saunthararajah, MD

Blood (2012) 120 (21): 1696.

https://doi.org/10.1182/blood.V120.21.1696.1696

Published: 2012

Journal Articles

Biological Rationale for the Favorable Clinical Outcomes of Patients Carrying SF3B1 Mutations in Myelodysplastic Syndromes with Ring Sideroblasts

Blood (2012) 120 (21): 922.

https://doi.org/10.1182/blood.V120.21.922.922

Published: 2012

NARROW

Extended Experience with a Very Low Dose, Metronomic, Subcutaneous Decitabine Regimen Intended to Deplete DNMT1 without Cytotoxicity

Coexistence of B-Cell Dyscrasia with Large Granular Lymphocytic Leukemia

Long-Term Experience with Large Granular Lymphocytic Leukemia Evolving after Solid Organ and Hematopoietic Stem Cell Transplantation

Predicting the Outcome in Egyptian Patients with Severe Aplastic Anemia Following Allogeneic Hematopoietic Stem Cell Transplantation Using Matched Sibling Donors

Comprehensive Characterization of Cytogenetic and Mutational Analysis of Acute Promyelocytic Leukemia: Is PML-Rara Everything?

Heterozygous CTC1 Variants in Acquired Bone Marrow Failure

The Mechanisms By Which Mutant-NPM1 Uncouples Differentiation from Proliferation Are Reversed By Several Drugs, Enabling Rational Multi-Component Non-Cytotoxic Differentiation Therapy

Origins of myelodysplastic syndromes after aplastic anemia

Clonal Events of Aplastic Anemia Related to the Evolution to Myelodysplastic Syndrome

The Mechanism By Which Mutant Nucleophosmin (NPM1) Creates Leukemic Self-Renewal Is Readily Reversed

Myelodysplastic Syndrome (MDS)-Determining Clonal Events at Presentation of Aplastic Anemia (AA)

Mechanisms of Resistance to 5-Azacytidine/Decitabine in MDS-AML and Pre-Clinical In Vivo Proof of Principle of Rational Solutions to Extend Response

Combination with Thu to Address Pharmacologic Limitations of Decitabine, Interim PK/PD from a Phase 1/2 Clinical Trial of Oral Thu-Decitabine in Sickle Cell Disease

A Specific Mechanism By Which NPM1 mutations Impede Myeloid Differentiation Also Explains The Link With DNMT3A Mutation

Splicing Factor 3b Subunit 1 ( SF3B1) mediates Mitochondrial Iron Overload In Myelodysplastic Syndromes With Ring Sideroblasts By Alternative Splicing Of Mitoferrin-1 ( SLC25A37 )

BCL -2 Family Of Genes Is a Key Regulator In The Pathogenesis Of SF3B1 Mutant and Wild Type MDS With Ring Sideroblasts and Represents a Novel Drug Target In This Disease

Splicing Factor 3b Subunit 1 (SF3B1) Heterozygous Mice Manifest a Hematologic Phenotype Similar To Low Risk Myelodysplastic Syndromes With Ring Sideroblasts

Extra-Nuclear Dislocation of PU.1 but Not CEBPA by Mutated NPM1 in AML Explains Lineage-Associations, ATRA Therapeutic Potential and DNMT3A Secondary Mutation.

Non-Cytotoxic Differentiation Therapy Based On Mechanism of Disease Produces Complete Remission in Myelodysplastic Syndromes (MDS) with High Risk Cytogenetics

Biological Rationale for the Favorable Clinical Outcomes of Patients Carrying SF3B1 Mutations in Myelodysplastic Syndromes with Ring Sideroblasts

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only